Safety, Simplicity and Success of the EpiLift System Were Main Themes During the Advanced Refractive Technologies Symposium at The 2005 ASCRS/ASOA Conference in Washington, D.C.; 'Exciting New Addition to My Practice,' Adds Foremost Expert.

SAN CLEMENTE, Calif. -- Topics ranging from new ways to avoid flap complications to reducing eye pain using novel approaches were several of the themes discussed at the VisiJet (VJET.OB) d.b.a. Advanced Refractive Technologies (ART) sponsored-symposium "Advanced Surface Ablation Through Precision Separation," which attracted a large number of physicians who came to hear a top panel of distinguished experts in the area of surface ablation refractive surgery. The symposium took place during the height of the American Society of Cataract and Refractive Surgery (ASCRS) conference, the 2nd largest eye surgery meeting in the world.

Dr. Terrence P. O'Brien, The Tom Clancy Professor of Ophthalmology and Director (Refractive Eye Surgery) at the Wilmer Eye Institute at John Hopkins University School of Medicine welcomed a panel that included Dr. Ron Krueger, Director of Refractive Surgery, Cole Eye Institute, The Cleveland Clinic; Dr. Bruce Larson, Associate Professor of Ophthalmology at Loyola Medical Center, Dr. Dimitri Azar, Massachusetts Eye & Ear Infirmary and Dr. Scott Barnes, Womack Army Hospital at Fort Bragg, NC. Refractive surgery specialist and foremost expert in the field, Dr. Kerry K. Assil from the Assil Sinskey Eye Institute was also on hand to comment on the impact the EpiLift system has had on his private practice.

Dr. Krueger's presentation entitled "Can we verify inflammation experimentally?" delved in to the histology of the EpiLift system. Dr. Krueger discussed how the EpiLift system uses a precise cleaving action to separate the epithelium between Lamina densa and Lamina lucida, which requires a tolerance of 0.8 micron. Dr. Kruger's conclusion was the EpiLift system is effective and safe.

Dr. Larson shared his findings for reducing the starburst effect, which occurred in 90% of early Lasik patients. Larson spoke at length about the Larson Glareometer, which he said is an effective tool for quantifying patients' results. He also discussed the evolution of the EpiLift technique and how it has changed in recent months. One technique he shared with the audience was the use of frozen balanced salt solution in completely eliminating post operative eye pain.

Dr. Azar's presentation "From Lasek to EpiLasik" discussed the toxicity issues surrounding ethanol alcohol Lasek, and found EpiLasik a more effective method of avoiding these issues entirely.

Dr. Barnes discussed the psychological need for a procedure such as the EpiLift system in avoiding flap complications in a military setting. Dr. Barnes shared initial results from a small patient trial with subjects who have undergone contralateral procedures (1 eye Epi/1 eye Lasik). Since introducing the Eplift system in October 2004, 64 soldiers have undergone the procedure with favorable and dramatic results.

"I find that I am at my most relaxed state when I use the EpiLift System on my patients," said Dr. Assil to the audience. "Just about every patient whom I might previously have considered for PRK, are suitable candidates for EpiLift. I consider this new technology an exciting new addition to my practice," he added.

For more information about the EpiLift System, log on to VisiJet.com

About Advanced Refractive Technologies

Advanced Refractive Technologies (ART) is a medical device company based in San Clemente, California focused on the development and marketing of innovative ophthalmic applications. The company recently received FDA approval for its EpiLift system, a next-generation, ophthalmic surgical device designed for separating corneal tissue. The EpiLift system is the cornerstone of a new improvement in Lasik surgery called Epi-LASIK. The EpiLift systems improve upon existing technologies with unique separating methods that can eliminate many postoperative problems. The EpiLift system is manufactured in Germany by Gebauer Medizintechnik GmbH.

In addition to the EpiLift system, ART is developing Pulsatome(R), which utilize the company's proprietary and patented waterjet technology. These products result in faster, safer and more efficacious procedures in two of the largest surgical markets in the world: refractive and cataract surgeries. The Pulsatome(R) cataract emulsifier, currently under development, is a device that uses pulsed waterjet technology to remove cataracts -- the most frequently performed surgical procedure in the world.

This release contains forward-looking statements that reflect the company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly, annual and other regular filings.